ZA200300439B - A bioavailable dosage form of loratadine. - Google Patents

A bioavailable dosage form of loratadine. Download PDF

Info

Publication number
ZA200300439B
ZA200300439B ZA200300439A ZA200300439A ZA200300439B ZA 200300439 B ZA200300439 B ZA 200300439B ZA 200300439 A ZA200300439 A ZA 200300439A ZA 200300439 A ZA200300439 A ZA 200300439A ZA 200300439 B ZA200300439 B ZA 200300439B
Authority
ZA
South Africa
Prior art keywords
loratadine
dosage form
oral dosage
particle size
microns
Prior art date
Application number
ZA200300439A
Other languages
English (en)
Inventor
Pananchukunath Manoj Kumar
Dinsheet Gupta
Rajiv Malik
Original Assignee
Ranbaxy Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11097068&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200300439(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ranbaxy Lab Ltd filed Critical Ranbaxy Lab Ltd
Publication of ZA200300439B publication Critical patent/ZA200300439B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
ZA200300439A 2000-07-17 2003-01-16 A bioavailable dosage form of loratadine. ZA200300439B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN651DE2000 IN192160B (cs) 2000-07-17 2000-07-17

Publications (1)

Publication Number Publication Date
ZA200300439B true ZA200300439B (en) 2004-02-10

Family

ID=11097068

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200300439A ZA200300439B (en) 2000-07-17 2003-01-16 A bioavailable dosage form of loratadine.

Country Status (12)

Country Link
US (1) US20020035119A1 (cs)
EP (1) EP1303276B1 (cs)
AT (1) ATE278404T1 (cs)
AU (1) AU2001274381A1 (cs)
BR (1) BR0112597A (cs)
DE (1) DE60106266T2 (cs)
DK (1) DK1303276T3 (cs)
ES (1) ES2230325T3 (cs)
IN (1) IN192160B (cs)
PT (1) PT1303276E (cs)
WO (1) WO2002005816A1 (cs)
ZA (1) ZA200300439B (cs)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1635847T3 (da) 2003-06-13 2019-10-28 Idh Holding Aps Behandling af symptomer forbundet med bakteriel vaginose
JP3881640B2 (ja) * 2003-08-08 2007-02-14 塩野義製薬株式会社 ロラタジンを含むドライシロップ剤
US20050069590A1 (en) * 2003-09-30 2005-03-31 Buehler Gail K. Stable suspensions for medicinal dosages
WO2006076097A2 (en) * 2004-12-07 2006-07-20 Nektar Therapeutics Stable non-crystalline formulation comprising losartan
US20070036859A1 (en) * 2005-08-11 2007-02-15 Perry Ronald L Sustained release antihistamine and decongestant composition
US9034381B2 (en) * 2005-11-10 2015-05-19 Alphapharm Pty Ltd Process to control particle size
US20100104636A1 (en) * 2006-12-21 2010-04-29 Panagiotis Keramidas Pharmaceutical Compound and Composition
AU2009273747A1 (en) * 2008-07-25 2010-01-28 Alphapharm Pty Ltd Atovaquone with a particle size diameter range (D90) of greater than 3 um to about 10 um

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3980778A (en) * 1973-10-25 1976-09-14 The Upjohn Company Anti-inflammatory steroid
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US6132758A (en) * 1998-06-01 2000-10-17 Schering Corporation Stabilized antihistamine syrup
IL131317A (en) * 1999-08-09 2006-08-01 Cts Chemical Ind Ltd Binder for pharmaceutical compositions

Also Published As

Publication number Publication date
AU2001274381A1 (en) 2002-01-30
DE60106266T2 (de) 2006-02-23
US20020035119A1 (en) 2002-03-21
HK1055256A1 (en) 2004-01-02
DE60106266D1 (de) 2004-11-11
EP1303276A1 (en) 2003-04-23
PT1303276E (pt) 2005-02-28
ATE278404T1 (de) 2004-10-15
WO2002005816A1 (en) 2002-01-24
DK1303276T3 (da) 2005-02-07
BR0112597A (pt) 2003-08-12
ES2230325T3 (es) 2005-05-01
IN192160B (cs) 2004-02-28
EP1303276B1 (en) 2004-10-06

Similar Documents

Publication Publication Date Title
US8501160B2 (en) Crush-resistant oxycodone tablets intended for preventing accidental misuse and unlawful diversion
US20030096791A1 (en) Taste masking of highly water-soluble drugs
AU2022220043A1 (en) Irak4 degraders and uses thereof
AU748396B2 (en) Composition
US6727243B1 (en) Compositions comprising cefuroxime axetil
KR20160054216A (ko) 콜린알포세레이트를 함유하는 정제 및 그 제조방법
KR20090113243A (ko) 강건한 서방형 제제
EP1303276B1 (en) A bioavailable dosage form of loratadine
CN113368071A (zh) 一种含盐酸伐地那非三水合物的口服固体制剂及其制备方法
JP2005522467A (ja) 新規医薬製剤としてのエピナスチン、ベラドンナ及びシュードエフェドリンの組み合わせ
KR20240148359A (ko) 특발성 폐섬유증 치료를 위한 불록시부티드의 용도
JP2001097856A (ja) 鎮咳剤
US20050084527A1 (en) Pharmaceutical formulations containing combinations of epinastine, pseudoephedrine, and methylephedrine
HK1055256B (en) A bioavailable dosage form of loratadine
JP2864737B2 (ja) 徐放性製剤用基剤並びに徐放性製剤及び該製剤の製造方法
JP2006028130A (ja) ピモベンダン経口投与製剤
EP1586313A1 (en) Pharmaceutical composition with metoclopramide and process for its preparation
JP2004010611A (ja) マスキング組成物
KR20090076946A (ko) 옥시모르폰의 강건한 서방형 제제
EP2736498B1 (en) Prolonged release pharmaceutical composition comprising galantamine and method for the preparation thereof
CN110711179A (zh) 一种含孟鲁司特钠的口崩片及其制备方法
CA2507609A1 (en) Method and compositions for treating anxiety
Vadsola et al. FORMULATION AND EVALUATION OF MOUTH DISSOLVING TABLET OF BAMBUTEROL HYDROCHLORIDE
Shiradkar et al. Mouth Disintegrating Tablets Of Taste-Masked Tramadol HCl
KR20180130682A (ko) 베포타스틴 또는 이의 약학적으로 허용 가능한 염을 포함하는 약제학적 제제